NEW YORK, NY — For immediate control of a hand eczema flare, the old soak and smear approach with moisturizers or corticosteroids might live on, but they are moving to the back of the shelf for ...

Hand eczema, or hand dermatitis, is an inflammatory skin condition. Swollen, itchy, scaly, discolored rashes form on the fingers and hands. The skin may blister and crack, and it can be painful. Hand ...

Please provide your email address to receive an email when new articles are posted on . In two phase 3 trials, delgocitinib cream improved hand eczema in a greater proportion of patients vs. vehicle.

A regulatory decision is expected in the second half of 2025. The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for delgocitinib cream as a treatment for ...

For many adults, the persistent itch and painful irritation on their hands isn’t just seasonal dryness, cold winter weather, ...

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI. Chronic hand eczema (CHE) ...

The campaign focuses on educating the one in 10 U.S. adults living with chronic hand eczema (CHE), particularly the one in three patients who have never heard the specific name of their condition.

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Please provide your email address to receive an email when new articles are posted on . Delgocitinib cream is an investigational, topical pan-Janus kinase inhibitor. Patients treated with delgocitinib ...

Treatment options for severe chronic hand eczema are limited and carry troublesome adverse effects. Delgocitinib cream had superior efficacy compared with oral alitretinoin for this patient population ...

San Diego — Data from an open-label extension study of delgocitinib cream reflects the positive phase 3 safety and efficacy results released > 1 year ago from two separate trials in patients with ...